Download PDF
Fortschr Neurol Psychiatr 2022; 90(01/02): 37-41
DOI: 10.1055/a-1677-4008
Skripte der Botulinumtoxin-Akademie

Botulinumtoxin – Therapie des Spasmus hemifacialis: Ein Update

Therapy of Hemifacial Spasm with Botulinum Toxin: an Update
Wolfgang H. Jost
1   Parkinson-Klinik Ortenau, Wolfach
,
Rainer Laskawi
2   Hals-Nasen-Ohrenklinik, Universitätsmedizin Göttingen, Göttingen
,
Anja Palmowski-Wolfe
3   Universitäts-Augenklinik, Universität Basel, Basel,Schweiz
,
Björn Spittau
4   Anatomie und Zellbiologie, Medizinische Fakultät OWL, Universität Bielefeld
,
Peter P. Urban
5   Asklepios Klinik Barmbek, Abt. für Neurologie, Hamburg
› Author Affiliations
› Further Information
    Permissions and Reprints

Zusammenfassung

Die Injektion von Botulinumtoxin gilt beim Spasmus hemifacialis (SHF) mittlerweile als Therapie der Wahl. Alle 3 Botulinumtoxin-A Präparate sind für diese Indikation zugelassen. Der SHF ist eine häufige Erkrankung, die gekennzeichnet ist durch unwillkürliche Kontraktionen der vom Nervus facialis innervierten Muskulatur einer Gesichtshälfte. Die Symptome können tonisch oder klonisch, intermittierend oder permanent auftreten. Die Diagnosestellung erfolgt klinisch. Zur Ausschlussdiagnostik sollte eine Magnetresonanztomografie des Schädels eingesetzt werden, die einen pathologischen Nerv-Gefäß-Kontakt nachweisen und alternative Ursachen ausschließen kann.

Abstract

Injections of botulinum toxin can be viewed by now as the therapy of choice in treating hemifacial spasm (HFS). Each of the three botulinum toxin-A preparations have been approved for this indication in Germany. HFS is a frequent disease characterized by involuntary contractions of the muscles of one half of the face innervated by the facial nerve. The symptoms can be either tonic or clonic, intermittant or permanent. Diagnosis is based purely on clinical observation. A magnetic resonance imagingof the skull is appropriate to demonstrate nerve-vessel contact as most frequent cause and to exclude other pathologies.

Schlüsselwörter

Botulinumtoxin - Spasmus hemifacialis - N. facialis

Key words

Botulinum toxin - hemifacial spasm - facial nerve


Publication History

Received: 13 September 2021

Accepted: 12 October 2021

Article published online:
12 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Jost WH, Laskawi R, Palmowski-Wolfe A, Urban PP. Therapie des Spasmus hemifacialis mit Botulinumtoxin. Fortschr Neurol Psych 2017; 85: 194-198
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Brissaud É. Anatomie du cerveau de l’homme; morphologie des hémisphères cérébraux, ou cerveau proprement dit. Masson; Paris: 1893
    CrossrefGoogle Scholar
  • 3 Jost WH. Hemifacial spasm. In: Kompoliti K, Verhagen Metman L eds. Encyclopedia of Movement Disorders. Academic Press; 2010. 2. 17-30
    CrossrefGoogle Scholar
  • 4 Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998; 21: 1740-1747
    CrossrefPubMedGoogle Scholar
  • 5 Micheli F, Scorticati MC, Gatto E. et al. Familial hemifacial spasm. Mov Disord 1994; 9: 330-332
    CrossrefPubMedGoogle Scholar
  • 6 Digre K, Corbett JJ. Hemifacial spasm: differential diagnosis, mechanism, and treatment. Adv Neurol 1988; 49: 151-176
    PubMedGoogle Scholar
  • 7 Baizabal-Carvallo JF, Jankovic J. Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol 2017; 264: 359-363
    CrossrefPubMedGoogle Scholar
  • 8 Abbruzzese G, Beradelli A, Defazio G. Hemifacial spasm. Handb Clin Neurol 2011; 100: 675-680
    CrossrefPubMedGoogle Scholar
  • 9 Galvez-Jimenez N, Hanson MR, Desai M. Unusual causes of hemifacial spasm. Semin Neurol 2001; 21: 75-83
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Oliveira LD, Cardoso F, Vargas AP. Hemifacial spasm and arterial hypertension. Mov Disord 1999; 14: 832-835
    CrossrefPubMedGoogle Scholar
  • 11 Babinski J. Hémispasme facial périphérique. Nouvelle Iconographie de la Salpétrière 1905; 18: 418-423
    PubMedGoogle Scholar
  • 12 Tan EK, Jankovic J. Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord 1999; 14: 345-349
    CrossrefPubMedGoogle Scholar
  • 13 Reimer J, Gilg K, Karow A. et al. Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 2005; 111: 64-70
    CrossrefPubMedGoogle Scholar
  • 14 Tan EK, Fook-Chong S, Lum SY, Lim E. Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). J Neurol Sci 2004; 219: 151-155
    CrossrefPubMedGoogle Scholar
  • 15 Auger RG. Hemifacial spasm: clinical and electrophysiologic observations. Neurology 1979; 29: 1261-1272
    CrossrefPubMedGoogle Scholar
  • 16 Wabbels B, Yaqubi A. Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters. J Neural Transm (Vienna) 2021; 128: 793-802
    CrossrefPubMedGoogle Scholar
  • 17 Tan EK, Chan LL, Lim SH. et al. Role of magnetic resonance imaging and magnetic resonance angiography in patients with hemifacial spasm. Ann Acad Med Singapore 1999; 28: 169-173
    PubMedGoogle Scholar
  • 18 Montero J, Junyent J, Calopa M. et al. Electrophysiological study of ephaptic axono-axonal responses in hemifacial spasm. Muscle Nerve 2007; 35: 184-188
    CrossrefPubMedGoogle Scholar
  • 19 Yamashita S, Kawaguchi T, Fukuda M. et al. Lateral spread response elicited by double stimulation in patients with hemifacial spasm. Muscle Nerve 2002; 25: 845-849
    CrossrefPubMedGoogle Scholar
  • 20 Costa J, Espirito-Santo C, Borges A. et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev 1; 2005: CD004899. DOI: 10.1002/14651858.CD004899.pub2
    PubMed
  • 21 Elston JS. Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry 1986; 49: 827-829
    CrossrefPubMedGoogle Scholar
  • 22 Park YC, Lim JK, Lee DK, SD Yi. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 1993; 8: 334-340
    CrossrefPubMedGoogle Scholar
  • 23 Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985; 103: 347-350
    CrossrefPubMedGoogle Scholar
  • 24 Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 1992; 15: 1045-1049
    CrossrefPubMedGoogle Scholar
  • 25 Sławek J, Bogucki A, Bonikowski M. et al. Botulinum toxin type-A preparations are not the same medications – clinical studies (Part 2). Neurol Neurochir Pol 2021; 55: 141-157
    CrossrefPubMedGoogle Scholar
  • 26 Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001; 248: 21-24
    CrossrefPubMedGoogle Scholar
  • 27 Dutton JJ, White JJ, Richard MJ. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. Ophthal Plast Reconstr Surg 2006; 22: 173-177
    CrossrefPubMedGoogle Scholar
  • 28 Laskawi R. Spasmus facialis. In: Laskawi R, Roggenkämper P Hrsg.: Botulinumtoxin-Therapie im Kopf-Halsbereich. . 90-101. Urban und Vogel; 2004
    CrossrefGoogle Scholar
  • 29 Laskawi R, Niemczewska A, Schneider S. et al. Änderung von Dosis und Injektionsmuster der Botulinumtoxin-Langzeittherapie fazialer Dyskinesien. Laryngorhinootologie 2014; 93: 186-192
    PubMedGoogle Scholar
  • 30 Cakmur R, Ozturk V, Uzunel F. et al. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 2002; 249: 64-68
    CrossrefPubMedGoogle Scholar
  • 31 Eleopra R, Tugnoli V, Caniatti L, De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996; 46: 1158-1160
    CrossrefPubMedGoogle Scholar
  • 32 Urban PP. Pregabalin as add-on treatment to botulinum toxin in idiopathic hemifacial spasm. Neurology 2006; 66: 1781
    CrossrefPubMedGoogle Scholar
  • 33 Sampaio C, Ferreira JJ, Simoes F. et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4:1. Mov Disord 1997; 12: 1013-1018
    CrossrefPubMedGoogle Scholar
  • 34 Colakoglu BD, Cakmur R, Uzunel F. Is it always necessary to apply botulinum toxin into the lower facial muscles in hemifacial spasm?: a randomized, single-blind, crossover trial. Eur Neurol 2011; 65: 286-290
    CrossrefPubMedGoogle Scholar
  • 35 Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: Long term treatment with either Botox® or Dysport®. J Neural Transm 2010; 117: 759-763
    CrossrefPubMedGoogle Scholar
  • 36 Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998; 64: 751-757
    CrossrefPubMedGoogle Scholar
  • 37 Jannetta PJ, Abbacy M, Maroon JC, Morales-Ramos F. Aetiology and definitive microsurgical treatment of hemifacial spasm. Operative technique and results in fourty-seven patients. J Neurosurg 1997; 47: 321-328
    CrossrefPubMedGoogle Scholar
  • 38 Loeser JD, Chen J. Hemifacial spasm: treatment by microsurgical facial nerve decompression. Neurosurgery 1983; 13: 141-146
    CrossrefPubMedGoogle Scholar
  • 39 Auger RG, Piepgras DG, Laws ER. Hemifacial spasm: results of microvascular decompression of the facial nerve in 54 patients. Mayo Clin Proc 1986; 61: 640-644
    CrossrefPubMedGoogle Scholar
  • 40 Jost W. Atlas der Botulinumtoxin-Injektion: 3. Aufl. Berlin: KVM-Verlag; 2018.
    PubMed